Literature DB >> 22020525

Inflammation, oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients.

Haimanot Wasse1, Rong Huang, Nawazish Naqvi, Eileen Smith, Dezhi Wang, Ahsan Husain.   

Abstract

PURPOSE: Intimal hyperplasia (IH), a well-recognized cause of dialysis vascular access failure, is generally believed to be an acquired pathologic lesion. Recent data suggests that IH is present prior to AVF creation. We sought to determine whether pre-existing inflammation and oxidation co-exist with IH prior to their incorporation into an AVF conduit, as their presence may predispose the AVF to further IH following AVF creation.
METHODS: At the time of first AV access surgery, vein segments were collected from ten Stage 4 and 5 CKD patients undergoing AVF creation 6-12 months prior to anticipated dialysis initiation. Morphometry and immunohistochemistry was performed to detect inflammatory markers IL-6, TGF-ß1, and TNFa, and markers of DNA oxidative damage (8-Hydroxy-2'-deoxyguanosine [HNE]) and lipid peroxidation (4-Hydroxy-2-Nonenal [8OHdG]).
RESULTS: The degree of IH severity was variable. IL-6, TGF-ß1, and TNFa co-localized with a-smooth muscle actin prominently within the venous intima and media. Although more diffuse, HNE and 8OHdG were intensely expressed in parallel with the inflammatory markers. In spite of these findings, however, neither extant IH nor the intensity of inflammatory or oxidative markers were associated with primary or secondary AVF failure at 12 month follow-up.
CONCLUSIONS: Not only does venous IH pre-exist, but inflammation and oxidation markers are present within veins used for the AVF conduit prior to its creation in CKD patients as early as one year before dialysis is commenced. Nevertheless, short and long-term AVF outcomes were not associated with the inflammatory or oxidative burden, suggesting the complexity of AVF dysfunction in humans with CKD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22020525      PMCID: PMC3366016          DOI: 10.5301/jva.5000024

Source DB:  PubMed          Journal:  J Vasc Access        ISSN: 1129-7298            Impact factor:   2.283


  15 in total

1.  Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis.

Authors:  Chi-Jen Chang; Po-Jen Ko; Lung-An Hsu; Yu-Shien Ko; Yu-Lin Ko; Chin-Fen Chen; Chiu-Ching Huang; Tsu-Shiu Hsu; Ying-Shiung Lee; Jong-Hwei S Pang
Journal:  Am J Kidney Dis       Date:  2004-01       Impact factor: 8.860

2.  Clinical practice guidelines for vascular access.

Authors: 
Journal:  Am J Kidney Dis       Date:  2006-07       Impact factor: 8.860

3.  Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access.

Authors:  M F Weiss; V Scivittaro; J M Anderson
Journal:  Am J Kidney Dis       Date:  2001-05       Impact factor: 8.860

4.  Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas.

Authors:  Sylvia Stracke; Klaus Konner; Isabella Köstlin; Reinhard Friedl; Peter M Jehle; Vinzenz Hombach; Frieder Keller; Johannes Waltenberger
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

5.  Severe venous neointimal hyperplasia prior to dialysis access surgery.

Authors:  Timmy Lee; Vibha Chauhan; Mahesh Krishnamoorthy; Yang Wang; Lois Arend; Meenakshi J Mistry; Mahmoud El-Khatib; Rupak Banerjee; Rino Munda; Prabir Roy-Chaudhury
Journal:  Nephrol Dial Transplant       Date:  2011-01-10       Impact factor: 5.992

6.  Lipid oxidation products and oxidized low-density lipoproteins impair platelet-derived growth factor receptor activity in smooth muscle cells: implication in atherosclerosis.

Authors:  Cecile Vindis; Isabelle Escargueil-Blanc; Koji Uchida; Meyer Elbaz; Robert Salvayre; Anne Negre-Salvayre
Journal:  Redox Rep       Date:  2007       Impact factor: 4.412

7.  Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts.

Authors:  P Roy-Chaudhury; B S Kelly; M A Miller; A Reaves; J Armstrong; N Nanayakkara; S C Heffelfinger
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

8.  Vascular access outcomes and medication use: a USRDS study.

Authors:  Alexander S Yevzlin; Emily L Conley; Robert J Sanchez; Henry N Young; Bryan N Becker
Journal:  Semin Dial       Date:  2006 Nov-Dec       Impact factor: 3.455

9.  Local activation of interleukin 6 signaling is associated with arteriovenous fistula stenosis in hemodialysis patients.

Authors:  Daniela Marrone; Giovanni Pertosa; Simona Simone; Antonella Loverre; Carmen Capobianco; Mario Cifarelli; Bruno Memoli; Francesco P Schena; Giuseppe Grandaliano
Journal:  Am J Kidney Dis       Date:  2007-05       Impact factor: 8.860

10.  Computational fluid dynamics and vascular access.

Authors:  Ulf Krueger; Juergen Zanow; Hans Scholz
Journal:  Artif Organs       Date:  2002-07       Impact factor: 3.094

View more
  33 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

Review 2.  Novel paradigms for dialysis vascular access: downstream vascular biology--is there a final common pathway?

Authors:  Timmy Lee
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

3.  Caspase-1 Plays a Critical Role in Accelerating Chronic Kidney Disease-Promoted Neointimal Hyperplasia in the Carotid Artery.

Authors:  Lucas M Ferrer; Alexandra M Monroy; Jahaira Lopez-Pastrana; Gayani Nanayakkara; Ramon Cueto; Ya-Feng Li; Xinyuan Li; Hong Wang; Xiao-Feng Yang; Eric T Choi
Journal:  J Cardiovasc Transl Res       Date:  2016-02-29       Impact factor: 4.132

4.  Reduced Expression of Glutathione S-Transferase α 4 Promotes Vascular Neointimal Hyperplasia in CKD.

Authors:  Jinlong Luo; Guang Chen; Ming Liang; Aini Xie; Qingtian Li; Qunying Guo; Rajendra Sharma; Jizhong Cheng
Journal:  J Am Soc Nephrol       Date:  2017-11-10       Impact factor: 10.121

5.  Molecular Targets for Improving Arteriovenous Fistula Maturation and Patency.

Authors:  Jolanta Gorecka; Arash Fereydooni; Luis Gonzalez; Shin Rong Lee; Shirley Liu; Shun Ono; Jianbiao Xu; Jia Liu; Ryosuke Taniguchi; Yutaka Matsubara; Xixiang Gao; Mingjie Gao; John Langford; Bogdan Yatsula; Alan Dardik
Journal:  Vasc Investig Ther       Date:  2019-10-09

Review 6.  The Biology of Hemodialysis Vascular Access Failure.

Authors:  Akshaar Brahmbhatt; Sanjay Misra
Journal:  Semin Intervent Radiol       Date:  2016-03       Impact factor: 1.513

7.  Relationship between kidney disease and endothelial function in peripheral artery disease.

Authors:  Karen C Chong; Christopher D Owens; Meyeon Park; Hugh F Alley; W John Boscardin; Michael S Conte; Warren J Gasper; S Marlene Grenon
Journal:  J Vasc Surg       Date:  2014-10-16       Impact factor: 4.268

8.  Histopathology of Veins Obtained at Hemodialysis Arteriovenous Fistula Creation Surgery.

Authors:  Charles E Alpers; Peter B Imrey; Kelly L Hudkins; Tomasz A Wietecha; Milena Radeva; Michael Allon; Alfred K Cheung; Laura M Dember; Prabir Roy-Chaudhury; Yan-Ting Shiu; Christi M Terry; Alik Farber; Gerald J Beck; Harold I Feldman; John W Kusek; Jonathan Himmelfarb
Journal:  J Am Soc Nephrol       Date:  2017-07-19       Impact factor: 10.121

9.  Vitamin D deficiency is associated with mortality and adverse vascular access outcomes in patients with end-stage renal disease.

Authors:  Joy P Walker; Jade S Hiramoto; Warren J Gasper; Philip Auyang; Michael S Conte; Joseph H Rapp; David H Lovett; Christopher D Owens
Journal:  J Vasc Surg       Date:  2014-02-28       Impact factor: 4.268

Review 10.  Vascular access in haemodialysis: strengthening the Achilles' heel.

Authors:  Miguel C Riella; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2013-04-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.